Lek recycles 92% of all waste generated
- The development and production sites in Mengeš and Ljubljana have been selected to run pilot projects to provide support for all the Novartis sites around the globe in achieving carbon neutrality, reducing the use of water and the amount of waste at sites.
- In 2018, Lek reached a 3% increase of efficient energy use, 9% increase of efficient use of water, and a 12% reduction of non-recyclable waste.
- By using modeling methodology, the Development Center Slovenia predicts the results of bioequivalence studies to reduce the time required for development and drug development risks.
- The USD 8.3 million worth of new laboratories for pharmaceutical and analytical development are about to open.
It is Lek’s innovation culture, achievements and ten-year tradition ofenergy management that contributed to the Novartis’ decision to entrust thesites in Slovenia to run a pilot project to implement the Novartis newenvironmental strategy. Experts working at the Mengeš and Ljubljana Site arealready searching for new ways to carbon, plastic, and water neutrality to beachieved by 2020 in Novartis.
In 2018, Lek improved its energy efficiency by 3% resulting in an increase in energy use of 1.3% despite a 4% volume increase in production. They have successfully introduced the active energy management project to monitor all energy systems in Ljubljana and Mengeš to achieve their optimum performance, which is also being introduced at the Prevalje and Lendava sites in 2019.
Additional measures were taken to improve energy efficiency, generating energy savings of 16.5 TJ and reducing CO2 emissions by 560 tons, which is equivalent to planting 28,000 new trees.* They increased their efficient use of water by 9% and reduced their non-recycled waste by 12%. “Lek now recycles nearly 92% of all waste generated. This is a 1% increase compared to the previous year”, said Mojca Bernik, Environmental Manager at Lek. “Despite a 4% volume increase in production, the total amount of waste generated remains at 2017 levels.”
By the proliferation of digitized processes they contribute to make treatments more affordable and to achieve long-term, sustainable pharmaceutical production. However, digitization is entering the drug development segment as well. At the Development Center Slovenia, they have been implementing modeling in drug development for a decade and are now applying it across all areas of development, not just in vitro/in vivo correlations. By using state-of-the-art digital technologies, researcher Jerneja Opara, PhD, developed a scientific methodology for predicting the results of bioequivalence studies, which significantly contributes to the superior performance of these studies conducted at Sandoz. Sandoz has also established itself as a pioneer in health digitalization and as a leading manufacturer of digitized medicines. This year, Sandoz’ digital therapeutics reSET and reSET-O (containing the active ingredient buprenorphine) became the first FDA-authorized prescription digital mobile medical application to treat Substance Use Disorder (SUD).
The construction of new laboratories at the Development Center Slovenia in Ljubljana nears completion. This extension will further increase the capacity of pharmaceutical and analytical development. In addition, it will consolidate its position as the leading Sandoz development center specializing in technologically demanding development projects.
In 2019, Lek has released an overview of environmental impacts for the tenth time and a sustainability report for the ninth time in a row. It has been created according to international standards EMAS, POR, GRI GS and in relation to the United Nations Sustainable Development Goals (SDGs). It is available at https://www.lek.si/en/corporate-responsibility/reporting/.
* The impact of reducing electricity consumption to reduce CO2 emissions is equivalent to the impact of tree planting; assuming a single tree absorbs 20 kg of CO2 per year.
Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 2 billion since 2003. More than half of this investment has been devoted to development, and the rest to modernize and expand our production capacities.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1,000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32